Novartis: Ovarian cancer drug disappoints in trial

May 27, 2010

(AP) -- Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

The drug, patupilone, failed to show improvements over existing drugs in 829 patients with advanced .

"Novartis does not plan to proceed with regulatory filings based on these data," the Basel-based company said.

Patupilone also is being tested for treatment of certain types of colorectal, lung and .

Shares in Novartis closed 1.6 percent higher at 51.85 Swiss francs ($45.01) in line with a general lift on the Zurich exchange.

shares

Related Stories

Recommended for you

Glucocorticoids offer long-term benefits for patients with Duchenne muscular dystrophy

November 22, 2017
Glucocorticoids, a class of steroid hormone medications often prescribed to patients with Duchenne muscular dystrophy (DMD), offer long-term benefits for this disease, including longer preservation of muscle strength and ...

Baby-boomers and millennials more afflicted by the opioid epidemic

November 21, 2017
Baby-boomers, those born between 1947 and 1964, experienced an excess risk of prescription opioid overdose death and heroin overdose death, according to latest research at Columbia University's Mailman School of Public Health. ...

Sensor-equipped pill raises technological, ethical questions

November 17, 2017
The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients ...

New painkillers reduce overdose risk

November 16, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have developed new opioid pain relievers that reduce pain on par with morphine but do not slow or stop breathing—the cause of opiate overdose.

Separating side effects could hold key for safer opioids

November 16, 2017
Opioid pain relievers can be extremely effective in relieving pain, but can carry a high risk of addiction and ultimately overdose when breathing is suppressed and stops. Scientists have discovered a way to separate these ...

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
1 / 5 (1) May 27, 2010
What a drag for Novartis!!! Not only do they lose billions in profits, but they have that much less capital to live up to the double-digit quarterly dividend that their shareholders demand.
This kind of failure is inevitable for as long as BigPharma relies on the "Profit Foremost" model of drug development. Currently, if a drug candidate shows any promise(as in, can we rush this to market?), then it will be fast-tracked in preference to another that may show greater effectiveness, but may take longer to develop, refine, and trial.
If it's all about cashflow and marketing, then the quality of the product is going to suffer, and so I laugh every time I see them step on their own dick like this. Just imagine if you or I indulged in this sort of planning. It would be just as wise to use a casino visit to determine your budget.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.